Recombinant Human Anti-CD30 x Anti-CD64 Bispecific Antibody (Fab-IgG) (FABIG-H284)

Recombinant Anti-CD30 x Anti-CD64 Bispecific Antibody (Fab-IgG) is designed to be expressed as three chains, assembling in vivo and resulting in the construct of Fab-IgG (Tandem Fab-Fc). Fab-IgG has standard Fab and Fc domains, with no mutations, which may permit it has similar affinity binding and PK profile comparable to the parental antibodies. This BsAb can retarget neutrophilscells to tumor cells. It is designed for the research of Neuroblastoma; Osteosarcoma; Hodgkin lymphoma; T cell lymphoma; Anaplastic large cell lymphoma (ALCL) therapy.

Datasheet INQUIRY

Specifications

Targets

CD30 & CD64

Type

Fab-IgG

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Neuroblastoma; Osteosarcoma; Hodgkin lymphoma; T cell lymphoma; Anaplastic large cell lymphoma (ALCL)

Targets

Target 1

CD30

Gene ID

943

UniProt ID

P28908

Alternative Names

TNFRSF8; tumor necrosis factor receptor superfamily, member 8; CD30; Ki-1; D1S166E; tumor necrosis factor receptor superfamily member 8; Ki-1 antigen; CD30L receptor; cytokine receptor CD30; lymphocyte activation antigen CD30

Target 2

CD64

Gene ID

2209

UniProt ID

P12314

Alternative Names

FCGR1A; Fc fragment of IgG receptor Ia; CD64; FCRI; CD64A; IGFR1; Cluster of Differentiation 64; FcγRI; FCGR1B; FCGR1C; immunoglobulin G Fc receptor high affinity I; Fc gamma RI

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Human Anti-CD30 x Anti-CD64 Bispecific Antibody (Fab-IgG) (FABIG-H284). Click the button below to contact us or submit your feedback about this product.

Recombinant Human Anti-CD30 x Anti-CD64 Bispecific Antibody (Fab-IgG) (CAT#: FABIG-H284)

Specifications

Targets

Customer Reviews and Q&As